Post-Financial Crisis Transaction Trends Of U.S. Biotechnology Firms by NC DOCKS at Appalachian State University & Williams, David
Archived version from NCDOCKS Institutional Repository http://libres.uncg.edu/ir/asu/ 
Post-Financial Crisis Transaction Trends Of 
U.S. Biotechnology Firms
By: David R. Williams and Carlton C. Young
Abstract
Transactions announcements can signal the health of an industry. This article examines all biotechnology transaction 
announcements occurring in the U.S. between 2010 and 2017. A baseline comparison to the prefinancial crisis 
transaction announcements of 2002 through 2006 is provided. Our study finds a significant rebound in the number 
of transactions during the time of study and continuing shifts by those on both ends of the transactions.
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INTRODUCTION
The transfer of knowledge and technology in the biotechnology industry has been of interest to practitioners, governments, and scholars for 
decades [1]. This is due to the continued growth in need 
to access resources and capabilities in this industry from 
outside the firm [2–4]. These transfers have taken several 
different forms (i.e., collaborations, firm acquisitions, 
etc.)[5], and involved several sectors of society—from the 
university to the financial industry [6]. It has been noted 
that these transactions were affected by the financial cri-
sis in the U.S. [7, 8], which lasted from December 2007 
through mid-year 2009 [9]. For example, within the bio-
technology industry there was a reduction in financing 
of firms via initial public offerings [10], venture capital 
investment [11], as well as out-licensing arrangements 
[12]. These and other financing issues led biotechnology 
firms in many cases to reduce or discontinue research 
and development programs during this time [7]. 
This article examines U.S. biotechnology transac-
tion announcements after the recent financial crisis. The 
study compares post financial transactions to a five-year 
pre-financial crisis aggregate. It reviews inter-firm trans-
action announcement activity surrounding the location 
(e.g. U.S., foreign), type of firm (e.g. private, publicly-
traded, non-profit), and form (e.g. collaboration, firm 
acquisition, license, etc.) of these transactions. This is 
important as the fluidity of transactions, in part, may 
Post Financial Crisis Transaction 
Trends of U.S. Biotechnology Firms
David r Williams
Professor, Department of Nutrition and Health Care Management, College of Health Sciences, Appalachian State University
Carlton C young
Professor of Healthcare Administration, College of Business,Mississippi State University, Riley Campus.
abstraCt
Transactions announcements can signal the health of an industry. This article examines all biotechnology 
transaction announcements occurring in the U.S. between 2010 and 2017. A baseline comparison to the pre-
financial crisis transaction announcements of 2002 through 2006 is provided. Our study fi nds a si gnificant 
rebound in the number of transactions during the time of study and continuing shifts by those on both ends of 
the transactions.
Keywords: Transaction announcements; Knowledge transfers; Post financial crisis
positively affect the economic health of these firms and 
the biotechnology industry in the U.S. and abroad [13]. 
It focuses on biotechnology firms transferring knowl-
edge because: 1) biotechnology represents a paradigm 
shift in drug discovery and development [14]; 2) there are 
few transactions from pharmaceutical firms to biotech-
nology firms; and 3) biotechnology firms typically lack 
the resources and leverage in transfer negotiations with 
larger pharmaceutical firms [15]. 
MeThODs
This article is based on data derived from biotechnol-
ogy transaction announcements from January 1, 2010 
through December 31, 2017. It also at times (when data 
are available) shows a baseline comparison to pre-finan-
cial crisis transactions occurring from January 1, 2002 
through December 31, 2006. It uses a database com-
piled by Levin and Associates. The primary sources for 
the announcements are from PR Newswire, PE Hub, 
and Seeking Alpha. The data reflect transactions where 
the originating firm is a biotechnology firm (i.e., phar-
maceutical firms transferring technology or knowledge 
are excluded). The data reflect transactions only where 
either the transferor or transferee is a U.S. based firm. 
For our post financial crisis analyses, there were 897 sep-
arate announcements, of which 892 were usable. There 
are 370 announcements in the comparison data years 
(2002-2006). 
The transactions differ from other sources in that 
it does not separate different transactions related to a 
given announcement. For example, if a biotechnology 
firm announces in one press release that it has entered 
into multiple licensing arrangements with another 
firm for multiple products, then this is considered one 
transaction. In a few cases, there were missing data for 
which the authors did an Internet search to complete 
the dataset. Based on a review of the announcement 
summary or an Internet search of the announcement, 
the authors categorized all transactions into the follow-
ing groupings: collaboration agreements, collaboration 
and licensing agreements, product acquisitions, rights 
or licenses, merger or reverse merger, full or partial 
equity acquisition of the firm, spin-off, and sell of busi-
ness line. Real numbers are presented in the figures. The 
narrative below uses both real numbers and percent-
ages at times.
TRaNsfeRs by yeaR, LOCaTION, 
aND Type
Figure 1 shows the total number of transaction 
announcements by year. After s wings u p a nd d own o f 
up to 40 percent from 2010 to 2013, overall transactions 
steadily increase by 176 percent from 2013 through 2017 
(Figure 1). Hence, the overall transaction market appears 
to have significantly rebounded from the financial crisis 
during the second half of the study. This compares with 
our baseline comparison years where from 2002 through 
2006 there were 67, 89, 76, 68, and 70 transactions, 
respectively. Additionally, in the baseline pre-crisis years 
the average year had 74 transactions compared with 112 
transactions on average post crisis—a 51 percent increase 
in transactions per year on average post crisis. 
Figure 2A shows whether the transferring firm 
(transferor) was a U.S or foreign firm. Overall, 707 (or 
79 percent) of the 892 transfer announcements were 
from U.S. firms transferring knowledge or technology 
to another firm. The percent of U.S. firms transferring 
knowledge or technology remained fairly constant at 
around 77 to 80 percent during this time. Figure 2B 
shows the transfer by country receiving (transferee) the 
transfer of knowledge or technology. Overall, U.S. firms 
received 673 (or 75 percent) of the transfers. This is the 
same as the baseline pre-crisis years (2002-2006) of 75 
percent as well. Unlike U.S. firms transferring technol-
ogy, there was greater variability in U.S. firms receiving 
knowledge or technology during the course of study—
from 63 percent in 2010 to 86 percent in 2014. This simi-
larly compares to our baseline pre-crisis years in which 
the U.S. firms saw a low of 66 percent in 2005 and a high 
of 83 percent in 2003. Additionally, overall, only 488 
(or 58 percent) of the 892 post crisis transfer announce-
ments involved U.S. firms both as transferor and trans-
feree. This is to say that 42 percent of the time either 
the buyer or seller was a foreign firm. The year 2010 was 
the peak year at 57 percent for both the transferor and 
figure 1: Transaction Announcements by Year.
transferee to be a U.S. firm, with 2014 being the low year 
at 35 percent for both firms being a U.S. company.
It also is important to know which type of firm 
(e.g. private, publicly traded, or non-profit organiza-
tion) is transferring knowledge or technology. Figure 3 
illustrates these transactions by type of transferor. As 
one would expect, overall, 61 percent of the time the 
firm transferring was a private firm. This is similar as 
our baseline pre-crisis comparison years of 60 percent. 
Private firms typically transfer knowledge or technology 
in order to receive funding for other efforts. This com-
pares with overall transfers of 34 percent and 4 percent 
for publicly traded firms and non-profit organizations, 
respectively. Our baseline pre-crisis transfers overall 
had 38 percent and 2 percent for publicly traded firms 
and non-profit organizations, respectively. However, 
there is great variation in transfers by type of firm over 
time. Private firms showed a low of 48 percent of trans-
fers in 2017 and a high of 72 percent in 2012. This is 
similar to our baseline pre-crisis comparison of a low 
of 53 percent (2003) and a high of 71 percent (2004). 
In 2015 post crisis publicly traded firms saw a low of 
27 percent. The high year was 2010 with 46 percent of 
transfers. Perhaps most interestingly, non-profit organi-
zation had two years (2010, 2012) of no announcements; 
yet in 2017 represent 13 percent of all announcements as 
transferors. 
Figure 4 shows the type of firm receiving (trans-
feree) the knowledge or technology. Overall, about 25 
percent of the time, the firm receiving the transfer was a 
private firm. This compares with 74 percent of the time 
the transferee is a publicly traded firm and less than 1 
percent of the time the transferee is a non-profit organi-
zation. Our baseline pre-crisis years show that 80 percent 
of the time the transferee is a publicly traded firm, 20 per-
cent of the time the firm is a private firm, and less than 1 
percent of the time the firm is a non-profit. For our post 
financial crisis years, the last three years of the study sees 
a shift in transferee on a percentage basis. At the expense 
figure 2a: Origin of Firm Generating Transaction.
figure 2b: Origin of Firm Receiving Transaction.
56
of publicly traded firms, private firms increase from 13 
percent in 2015 to 40 percent in 2017.
Figure 5 illustrates whether the firm receiving the 
knowledge or technology (transferee) was a biotechnol-
ogy, pharmaceutical or other type of firm. Other types of 
figure 3: Type of Firm Transferring Technology or Knowledge.
figure 4: Type of Firm Receiving Technology or Knowledge.
firms include medical device makers, informatics firms, 
and private equity firms. These data are not provided 
in our baseline comparison years. Overall, biotechnol-
ogy firms represented 53 percent of the firms, followed 
by pharmaceutical firms at 39 percent, and other firms 
at 8 percent. Interestingly, pharmaceutical firms in 2010 
represented 73 percent of the transferee firms, but ended 
at 34 percent in 2017. It should be noted again that the 
study does not include pharmaceutical technology or 
knowledge being transferred. Nevertheless, the increase 
in real numbers and on a percentage basis of biotech-
nology firms transferring knowledge and technology to 
other biotechnology firms is significant and shows that 
the market for biotechnology is changing away from 
one dominated by pharmaceutical firms as the trans-
feree. Thus, during this time period, there appears to be 
increasing development of an inter-industry market (i.e., 
biotechnology-biotechnology) as compared to an inter-
sector market (i.e., biotechnology-pharmaceutical).
TRaNsfeRs by fORM
Figure 6 illustrates the form of transaction overall and 
by year. Each transaction announcement summary was 
read and categorized. The largest category overall post 
crisis was rights or license agreement announcements. 
As it was difficult to distinguish at times between a 
transfer of rights and a license (i.e., non-exclusive), the 
two forms were combined. These represent almost 37 
percent of all announcements during the eight-year 
period (2010-2017). An example of this is Halozyme’s 
granting a license for rHuPH20 to Intrexon. This com-
pares with our baseline pre-crisis years (2002-2006) of 
licensing arrangements representing only 19 percent. 
Full or partial equity acquisition was the second largest 
form post crisis. Here, firms typically are acquiring the 
equity of another firm to gain access to not only technol-
ogy, but also the tacit (non-codified, know-how) knowl-
edge that resides within individuals [16]. An example of 
this is Sanofi’s acquisition of Genzyme. For our baseline 
pre-crisis years (2002-2006), acquisitions represent the 
largest form of transaction at 41 percent. The third high-
est percentage post crisis resides with collaborations, 
with this form representing almost 11 percent. An exam-
ple of this is Isis Pharmaceuticals entering into a collabo-
ration agreement with GlaxoSmithKline to develop and 
commercialize microRNA therapeutics for rare diseases. 
Mergers and reverse mergers represent over 4 percent. 
For our baseline pre-crisis years (2002-2006) mergers 
and reverse mergers represent 10 percent. The remainder 
represents collaborations and licensing arrangements, 
product acquisitions, and spin-offs. These last three areas 
represent about 7 percent of all transactions collectively 
post crisis.
figure 5: Biotechnology Firm or Pharmaceutical Firm Transferee.
figure 7: Form of Transaction Over Time.
figure 6: Form of Transaction (2010–2017).
In examining the form over time, one immediately 
sees the dramatic increase in licensing arrangements over 
the last few years of the study. This is shown in Figure 7. 
Indeed, licensing represents 28 percent, 42 percent, and 
57 percent of total transactions per year in 2015, 2016, 
and 2017, respectively. Percentage-wise, this mainly 
comes at the expense of full and partial equity acquisi-
tions during this same time period. Whereas, equity 
acquisitions increase from 24 percent to 54 percent of all 
transactions from 2010 to 2013, they decline to 24 percent 
by 2017. Yet, both licensing and equity acquisitions have 
greater numbers of transactions the last three years of 
the study than other years, collectively. Both the increase 
in overall numbers and the shift percentage-wise toward 
licensing during the later part of the study may be due to 
an improvement of financial markets (e.g. venture capi-
tal, IPO) that are available to biotechnology firms, with 
licensing typically a more preferred method of financing 
than equity acquisition.
CONCLUsION
Market activity at times can be an indicator of the 
health of an industry. Biotechnology firms have relied 
on markets in the various forms noted in this article to 
gain access to knowledge, technologies, and capital. The 
financial crisis of 2007-2009 in many regards stagnated 
these markets and thus the biotechnology industry. The 
present article has shown that to a large extent the mar-
ket for biotechnology transfers has not only recovered, 
but also flourished with activity. It has also shown that 
post financial crisis there has been a recent shift within 
this market with respect to the growing global nature of 
these transfers.
Perhaps, the most important aspect relates to the 
increased activity of private firms and biotechnology 
firms receiving knowledge and technologies (i.e., being 
transferees) at a greater rate during the later stages of 
the study. This, combined with the recent increase in 
licensing agreements on a percentage basis, points to a 
more developed biotechnology transactions market and 
one lessening its reliance upon pharmaceutical firms 
for financing, with these firms, perhaps, being able to 
go further to bring products and technologies on their 
own than in years past [8]. Further research is needed to 
understand the scope of the apparent lessening of depen-
dence of these firms.
The study is not without limitations. First, although 
the study is consistent in its method, it is not very fine 
grained as it examines transaction announcements 
and does not disaggregate the various elements in each 
announcement. Likewise, the study does not follow the 
different segments in the market due to the difficulty to 
at times categorize firms that pursue multiple diseases, 
treatment modalities, or applications. Nor does the study 
address potential distortions in the market via differ-
ent segments movements (e.g. gene therapy and cancer 
immunotherapy). Additionally, the authors did not have 
access to data during the crisis. It would be interesting 
to compare these crisis (2007–2009) data to the pre – 
and post financial crisis results. The study only exam-
ines U.S. firms transferring knowledge and technologies 
and thus, does not study the amount, type, or effect of 
other countries’ transfers on U.S. transfers. Nor did it 
study transfers originating from pharmaceutical firms. 
It would be insightful to compare pharmaceutical firm to 
biotechnology firm transfers over time. Further research 
is needed in these areas.
Nevertheless, the study verifies that the transaction 
market has rebounded and matured. It appears to have 
shifted away from one mainly reliant on established, 
publicly traded pharmaceutical firms to a transaction 
market with a more global reach and more driven by bio-
technology firms themselves.
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